Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02954991
Title Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.